Literature DB >> 22318358

Flow cytometric evaluation of the effects of 3-bromopyruvate (3BP) and dichloracetate (DCA) on THP-1 cells: a multiparameter analysis.

Harrie A Verhoeven1, Leo J L D van Griensven.   

Abstract

Two human leukemia cells K562 and THP-1, the breast cancer lines MCF-7 and ZR-75-1, and the melanoma line MDA-MB-435S were compared by flowcytometry for their behaviour at increasing levels of 3BP. K562 and THP-1 responded to 3BP by membrane depolarization and increased ROS; MCF-7 and ZR-75-1 showed decreased polarization and low ROS increase; MDA-MB-435S had limited depolarization and no ROS increase. THP-1 cells exposed to a range of 3BP concentrations in combination with DCA showed increase of polarization, slight ROS increase, and weakened nuclear integrity. 3BP and DCA show no synergism, but have complementary destructive effects on THP-1 cells. The data led to the conclusion that the THP-1 cells do not carry a functional membrane monocarboxylate transporter (MCT) or that 3BP circumvents MCT binding and can enter these cells independently.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22318358     DOI: 10.1007/s10863-012-9414-7

Source DB:  PubMed          Journal:  J Bioenerg Biomembr        ISSN: 0145-479X            Impact factor:   2.945


  30 in total

1.  Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETC.

Authors:  Luke H Stockwin; Sherry X Yu; Suzanne Borgel; Chad Hancock; Tracy L Wolfe; Lawrence R Phillips; Melinda G Hollingshead; Dianne L Newton
Journal:  Int J Cancer       Date:  2010-12-01       Impact factor: 7.396

2.  Hexokinase isozymes in human neoplastic and fetal tissues: the existence of hexokinase II in malignant tumors and in placenta.

Authors:  R Kamel; F Schwarzfischer
Journal:  Humangenetik       Date:  1975-11-06

3.  Anticancer drugs that target metabolism: Is dichloroacetate the new paradigm?

Authors:  Ioanna Papandreou; Tereza Goliasova; Nicholas C Denko
Journal:  Int J Cancer       Date:  2010-12-07       Impact factor: 7.396

Review 4.  The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation.

Authors:  A P Halestrap; N T Price
Journal:  Biochem J       Date:  1999-10-15       Impact factor: 3.857

Review 5.  Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen.

Authors:  Peter L Pedersen
Journal:  J Bioenerg Biomembr       Date:  2007-06       Impact factor: 2.945

6.  Establishment and characterization of a human acute monocytic leukemia cell line (THP-1).

Authors:  S Tsuchiya; M Yamabe; Y Yamaguchi; Y Kobayashi; T Konno; K Tada
Journal:  Int J Cancer       Date:  1980-08       Impact factor: 7.396

7.  Erythroid differentiation sensitizes K562 leukemia cells to TRAIL-induced apoptosis by downregulation of c-FLIP.

Authors:  Ville Hietakangas; Minna Poukkula; Kaisa M Heiskanen; Jarkko T Karvinen; Lea Sistonen; John E Eriksson
Journal:  Mol Cell Biol       Date:  2003-02       Impact factor: 4.272

8.  Establishment and characterization of three new continuous cell lines derived from human breast carcinomas.

Authors:  L W Engel; N A Young; T S Tralka; M E Lippman; S J O'Brien; M J Joyce
Journal:  Cancer Res       Date:  1978-10       Impact factor: 12.701

9.  Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review.

Authors:  Paolo E Porporato; Suveera Dhup; Rajesh K Dadhich; Tamara Copetti; Pierre Sonveaux
Journal:  Front Pharmacol       Date:  2011-08-25       Impact factor: 5.810

Review 10.  False positive and false negative FDG-PET scans in various thoracic diseases.

Authors:  Jung Min Chang; Hyun Ju Lee; Jin Mo Goo; Ho-Young Lee; Jong Jin Lee; June-Key Chung; Jung-Gi Im
Journal:  Korean J Radiol       Date:  2006 Jan-Mar       Impact factor: 3.500

View more
  3 in total

1.  3-Bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective "small molecule" anti-cancer agent taken from labside to bedside: introduction to a special issue.

Authors:  Peter L Pedersen
Journal:  J Bioenerg Biomembr       Date:  2012-02       Impact factor: 2.945

Review 2.  The anticancer agent 3-bromopyruvate: a simple but powerful molecule taken from the lab to the bedside.

Authors:  J Azevedo-Silva; O Queirós; F Baltazar; S Ułaszewski; A Goffeau; Y H Ko; P L Pedersen; A Preto; M Casal
Journal:  J Bioenerg Biomembr       Date:  2016-07-25       Impact factor: 2.945

3.  Real-time imaging of microparticles and living cells with CMOS nanocapacitor arrays.

Authors:  C Laborde; F Pittino; H A Verhoeven; S G Lemay; L Selmi; M A Jongsma; F P Widdershoven
Journal:  Nat Nanotechnol       Date:  2015-08-03       Impact factor: 39.213

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.